<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="97462">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01921257</url>
  </required_header>
  <id_info>
    <org_study_id>CP009</org_study_id>
    <nct_id>NCT01921257</nct_id>
  </id_info>
  <brief_title>Paediatric Safety Study in Cat-PAD</brief_title>
  <official_title>A Multi-Centre, Single-Blind Study to Assess the Safety of Cat-PAD in Cat Allergic Paediatric Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Circassia Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>inVentiv Health Clinical</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Circassia Limited</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Study to Assess the Safety of Cat-PAD in Cat Allergic Paediatric Subjects
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>August 2013</start_date>
  <completion_date type="Anticipated">December 2014</completion_date>
  <primary_completion_date type="Anticipated">December 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Caregiver), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Proportion and frequency of Adverse events</measure>
    <time_frame>up to 36 weeks after start of treatment</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>To evaluate the safety and tolerability of Cat-PAD in paediatric subjects aged 5 to &lt;12 years.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">12</enrollment>
  <condition>Rhinoconjunctivitis</condition>
  <arm_group>
    <arm_group_label>Treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cat-PAD and Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cat-PAD</intervention_name>
    <arm_group_label>Treatment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        -  Inclusion Criteria

               -  Male or female, aged 5-12 years.

               -  Moderate to severe rhinoconjunctivitis on exposure to cats for at least 2 years.

               -  Subjects may optionally also have GINA Step 1 controlled asthma.

               -  Positive skin prick test to cat hair.

               -  Cat dander specific IgE â‰¥0.35 kU/L.

          -  Exclusion Criteria

               -  Asthma falling under the GINA definitions &quot;partly controlled&quot; and &quot;uncontrolled&quot;
                  or Steps 2 to 5.

               -  FEV1 &lt;80% of predicted.

               -  Clinically relevant abnormalities detected on physical examination.

               -  History of severe drug allergy, severe angioedema or anaphylactic reaction to
                  food.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>5 Years</minimum_age>
    <maximum_age>11 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Lorenz Hubner</last_name>
    <email>lorenz.huebner@inventivhealth.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Peninsula Research Associates Inc</name>
      <address>
        <city>Rolling Hills Estate</city>
        <state>California</state>
        <zip>90274</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Lawrence Sher, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Allergy Associates Research Center</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Anthony Montanaro, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2014</verification_date>
  <lastchanged_date>February 3, 2014</lastchanged_date>
  <firstreceived_date>July 17, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Cat Allergy</keyword>
  <keyword>Rhinoconjunctivitis</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>No</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Conjunctivitis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
